We are live on ! Find out more
C

Chescapmanager Portfolio holdings

AUM $1.12B
1-Year Est. Return 67.49%
This Fund
S&P 500
This Quarter Est. Return
+3.52%
1 Year Est. Return
+67.49%
3 Year Est. Return
+215.18%
5 Year Est. Return
+141.46%
10 Year Est. Return
–
AUM
$427M
AUM Growth
-$2.33M
Cap. Flow
-$15.5M
Cap. Flow %
-3.64%
Top 10 Hldgs %
60.62%
Holding
44
New
2
Increased
8
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
SNOW icon
Snowflake
SNOW
+$11.4M
2
TGT icon
Target
TGT
+$9.82M
3
BWXT icon
BWX Technologies
BWXT
+$6.7M
4
U icon
Unity
U
+$2.46M
5
OWL icon
Blue Owl Capital
OWL
+$792K

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$6.46M
2
FUN icon
Cedar Fair
FUN
+$6.03M
3
CZR icon
Caesars Entertainment
CZR
+$4.37M
4
TBPH icon
Theravance Biopharma
TBPH
+$3.25M
5
FLEX icon
Flex
FLEX
+$3.19M

Sector Composition

Rank Sector Weight
1 Industrials 17.44%
2 Consumer Discretionary 15.4%
3 Technology 13.35%
4 Healthcare 10.59%
5 Consumer Staples 8.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LAZR
26
DELISTED
Luminar Technologies
LAZR
$4.49M 1.05%
60,481
– –
GRAB icon
27
Grab
GRAB
$13.7B
$4.19M 0.98%
1,300,138
-75,000
-5% -$215K
OWL icon
28
Blue Owl Capital
OWL
$6.54B
$4.1M 0.96%
387,099
+75,000
+24% +$792K
NVDA icon
29
NVIDIA
NVDA
$4.76T
$2.92M 0.69%
200,000
– –
PRDS
30
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$861K 0.2%
509,387
+147,671
+41% +$187K
CZR icon
31
Caesars Entertainment
CZR
$6.1B
$833K 0.2%
20,031
-98,100
-83% -$4.37M
DNA icon
32
Ginkgo Bioworks
DNA
$487M
$656K 0.15%
9,707
– –
NOMD icon
33
Nomad Foods
NOMD
$1.67B
$608K 0.14%
35,293
-48,173
-58% -$763K
KROS icon
34
Keros Therapeutics
KROS
$202M
$485K 0.11%
10,105
– –
NVTS icon
35
Navitas Semiconductor
NVTS
$2.78B
$195K 0.05%
55,666
-557,257
-91% -$2.39M
GRABW icon
36
Grab Holdings Warrant
GRABW
$520K
$54K 0.01%
100,000
– –
DNA.WS
37
DELISTED
Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
$21K ﹤0.01%
103,521
– –
CZOO.WS
38
DELISTED
Cazoo Group Ltd Redeemable Warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
CZOO.WS
$3K ﹤0.01%
312,500
– –
BMY icon
39
Bristol-Myers Squibb
BMY
$128B
– –
-90,852
Closed -$6.46M
FLEX icon
40
Flex
FLEX
$42.5B
– –
-254,063
Closed -$3.19M
GOOGL icon
41
CALL
Alphabet (Google) Class A
GOOGL
$3.99T
– –
-100,000
Closed -$9.56M
XLE icon
42
CALL
State Street Energy Select Sector SPDR ETF
XLE
$38.8B
– –
-400,000
Closed -$14.4M
IS
43
DELISTED
ironSource Ltd.
IS
– –
-720,383
Closed -$2.48M
1
2

Similar funds

CT
Caldwell Trust Venice, Florida $1.12B AUM 21.31% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM
PTC
Private Trust Company Cleveland, Ohio $1.12B AUM 21.35% 1-Year Est. Return
SL
Salomon & Ludwin Richmond, Virginia $1.12B AUM 14.38% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
JAFL
Jay A. Fishman Ltd Troy, Michigan $1.12B AUM 32.75% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Chescapmanager's Q4 2022 Portfolio in Review

As of Q4 2022, Chescapmanager held 44 positions worth $427M, down 0.54% from $429M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Chescapmanager withdrew a net $15.5M in Q4 2022, closing 5 positions and reducing 9 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $6.46M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 17% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Chescapmanager opened a new position in Target worth $9.33M.

  • Chescapmanager's largest Q4 2022 buy was Target: 62,590 shares worth $9.33M.
  • Chescapmanager added most to Snowflake in Q4 2022, an estimated $11.4M increase.
  • Chescapmanager's biggest Q4 2022 reduction was Cedar Fair, cutting an estimated $6.03M.
  • Chescapmanager fully exited Bristol-Myers Squibb in Q4 2022, selling an estimated $6.46M.
  • Chescapmanager's ten largest holdings make up 61% of its $427M portfolio in Q4 2022.
  • Chescapmanager opened 2 new positions and closed 5 in Q4 2022.
  • Chescapmanager's portfolio value fell 0.54% quarter-over-quarter to $427M.

Based on Chescapmanager's 13F filing for Q4 2022, filed 14 Feb 2023.